Who makes Naïve patients - ACO therapy?

Naïve patients - ACO therapy is developed by National Liver Institute, Egypt.

What development phase is Naïve patients - ACO therapy in?

Naïve patients - ACO therapy is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

Naïve patients - ACO therapy

National Liver Institute, Egypt · FDA-approved active Small molecule Quality 0/100

At a glance

Generic name	Naïve patients - ACO therapy
Sponsor	National Liver Institute, Egypt
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) (PHASE1, PHASE2)
A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma (PHASE3)
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma (PHASE1, PHASE2)
Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Naïve patients - ACO therapy CI brief — competitive landscape report
Naïve patients - ACO therapy updates RSS · CI watch RSS
National Liver Institute, Egypt portfolio CI